Navigation Links
Cambrex Reports Third Quarter 2011 Results
Date:11/3/2011

EAST RUTHERFORD, N.J., Nov. 3, 2011 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM) reports third quarter results for the period ended September 30, 2011.

Highlights

  • Reported sales increased by 17.9%, and excluding the impact of foreign currency, sales increased 10.9% compared to the third quarter of 2010.
  • EBITDA was $11.1 million in the quarter, an increase of 30.2% compared to Adjusted EBITDA of $8.5 million in the third quarter of 2010.
  • Debt, net of cash was $69.3 million at the end of the quarter, an improvement of $6.2 million during the quarter which includes a negative $2.6 million currency impact on foreign cash balances.
  • New $250 million five-year revolving credit facility entered into on November 2, 2011 provides sufficient access to capital to execute growth plans.

  • Basis of ReportingThe Company has provided a reconciliation from GAAP amounts to adjusted amounts at the end of this press release.  Management believes that the adjusted amounts provide a more meaningful representation of the Company's operating results for the periods presented due to the magnitude and nature of certain expenses recorded.

    Third Quarter of 2011 Operating Results – Continuing OperationsSales in the third quarter of 2011 of $58.2 million were 17.9% higher than the third quarter of 2010.  Excluding a 7.0% favorable impact of foreign exchange, reflecting a weaker U.S. dollar, sales increased 10.9%. The increase is primarily due to higher volumes of an active pharmaceutical ingredient ("API") for a customer who experienced a disruption in its supply chain for most of 2010, higher volumes of controlled substances, products utilizing the Company's drug delivery technology and a recently approved innovator product. These increases were partially offset by lower pricing across several product categories, lower sales of generic APIs and lower custom development shipments.  

    Gross margins in the third quarter of 2011 increased to 30.6% from 28.6% in the third quarter of 2010.  Excluding a favorable impact from foreign currency, third quarter of 2011 margins decreased to 27.3%.  The decline in currency adjusted gross margins was a result of lower pricing partially offset by higher production volumes and favorable product mix.  

    Selling, General and Administrative Expenses in the third quarter of 2011 were $9.8 million compared to $7.9 million in the same period last year.  The increase is primarily due to increased personnel costs and foreign exchange.

    Operating Profit increased to $5.4 million in the third quarter of 2011 from $1.3 million in the third quarter of 2010.  Operating Profit in the third quarter of 2011 increased $2.2 million compared to 2010 Adjusted Operating Profit of $3.2 million for the same period in 2010, driven primarily by favorable foreign exchange, higher sales volumes and favorable product mix partially offset by lower pricing and higher operating expenses.

    Equity in Losses of Partially-Owned Affiliate of $0.5 million in the third quarter of 2011 represents the Company's share of losses in Zenara Pharma, a pharmaceutical company focused on the formulation of finished dosage form products.  Cambrex acquired a 51% stake in Zenara during the fourth quarter of 2010.  The Company's share of Zenara's losses includes $0.3 million of amortization of intangibles and depreciation.

    Net Interest Expense decreased to $0.6 million in the third quarter of 2011 from $1.2 million in the third quarter of 2010.  This decrease is primarily due to the maturing of the Company's fixed interest rate swaps in October 2010.

    The Provision for Income Taxes totaled $1.2 million in the third quarter of 2011.  The Company's effective tax rate has been and is expected to remain highly sensitive to the geographic mix of income due to the Company's inability to recognize tax benefits where there has been a recent history of losses, primarily in the U.S.

    Income from continuing operations for the third quarter of 2011 was $3.1 million or $0.10 per share compared to a loss from continuing operations of $1.3 million or $0.04 per share in the third quarter of 2010.

    Capital expenditures and depreciation for the third quarter of 2011 were $4.7 million and $5.7 million compared to $3.5 million and $5.3 million in the third quarter of 2010, respectively.

    On November 2, 2011, the Company entered into a $250 million five-year syndicated senior revolving credit facility, replacing the Company's existing facility that was set to expire in April 2012.  The Company will pay interest on the facility at LIBOR plus 1.75% to 2.50% based upon certain financial measurements.  The facility also includes financial covenants regarding interest coverage and leverage ratios.

    Steven M. Klosk, President and Chief Executive Officer, said, "I am pleased with our third quarter performance with increased revenues from custom manufacturing, controlled substances and drug delivery products.  While generic API revenues were slightly lower during the quarter, incoming orders remain strong for this product category.  We continue to focus on generating free cash flow, lowering our production costs and developing new products to support continued growth."

    Guidance – Continuing OperationsThe Company currently expects that full year 2011 sales, excluding the impact of foreign currency, will increase between 5% and 7% versus 2010, and that full year 2011 EBITDA will be between $44 and $48 million.  EBITDA guidance is for continuing operations and excludes the impact of any M&A or restructuring activities.  The above guidance does not reflect Zenara, which is accounted for using the equity method, and as such is not consolidated into the Company's results.  Cambrex's income statement reflects 51% of Zenara's net results as Equity in Losses of Partially-Owned Affiliate.  For 2011, the Company continues to expect Zenara to have revenues in the low to mid single digit millions and a small EBITDA loss.

    Capital expenditures are expected to be approximately $14 to $16 million and depreciation is expected to be $22 to $24 million in 2011.

    The financial information contained in this press release is unaudited, subject to revision and should not be considered final until the Company's third quarter 2011 Form 10-Q is filed with the SEC.

    Conference Call and WebcastThe Conference Call to discuss third quarter of 2011 results will begin at 8:30 a.m. Eastern Time on Friday, November 4, 2011 and last approximately 45 minutes.  Those wishing to participate should call 1-800-723-6751 for domestic and +1-785-830-7980 for international.  Please use the pass code 6146431 and call approximately 10 minutes prior to start time.  A webcast is available from the Investors section on the Cambrex website located at www.cambrex.com and can be accessed for 30 days following the conference call.  A telephone replay of the conference call will be available through Friday, November 11, 2011 by calling 1-888-203-1112 for domestic and +1-719-457-0820 for international.  Please use the pass code 6146431 to access the replay.  

    Forward Looking StatementsThis document contains “forward-looking statements,” including statements regarding expected performance, especially expectations with respect to sales, gross margins, operating expenses, earnings per share, cash flows, capital expenditures, acquisitions, divestitures, collaborations, other expansion opportunities and those set forth under the heading “Guidance – Continuing Operations,” including the Company’s expectation that full year 2011 sales, excluding the impact of foreign currency, will increase between 5% and 7% versus 2010, that full year 2011 EBITDA will be between $44 and $48 million, that Zenara will have revenues in the low to mid single digit millions and a small EBITDA loss, that capital expenditures will be approximately $14 to $16 million and that depreciation will be $22 to $24 million in 2011.  These statements may be identified by the fact that they use words such as “expects,” “anticipates,” “intends,” “estimates,” “believes” or similar expressions.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations.  The factors described in Item 1A of Part I of the Company’s Annual Report on Form 10-K for the period ended December 31, 2010, captioned “Risk Factors,” or otherwise described in the Company’s filings with the Securities and Exchange Commission, as well as any cautionary language in the Company’s Annual Report on Form 10-K for the period ended December 31, 2010, provide examples of such risks and uncertainties that may cause the Company’s actual results to differ materially from the expectations the Company describes in its forward-looking statements, including but not limited to, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation and regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company’s public filings, changes in foreign currency exchange rates, uncollectable receivables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, and the Company’s ability to receive regulatory approvals for its products.

    For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex 2010 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the U.S. Securities and Exchange Commission.  

    About CambrexCambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  We offer Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products.  For more information, please visit www.cambrex.com.   CAMBREX CORPORATIONStatements of Profit and LossFor the Quarters Ended September 30, 2011 and 2010(in thousands, except per-share data)20112010% of% ofAmountSalesAmountSalesGross Sales

    $

    58,203$

    49,356Commissions, Allowances and Rebates412492Net Sales57,79148,864Other1,364(1,090)Net Revenues59,15547,774Cost of Goods Sold41,32671.0%33,66468.2%Gross Profit17,82930.6%14,11028.6%Operating ExpensesSelling, General and Administrative Expenses9,81816.9%7,87916.0%Research and Development Expenses2,6154.5%3,0806.2%Restructuring Expenses--1,1872.4%Merger and Acquisition Expenses--7111.4%Total Operating Expenses12,43321.4%12,85726.0%Operating Profit5,3969.3%1,2532.5%Other Expenses:Interest Expense, net5641,233Other Expenses, net1452Equity in Losses of Partially-Owned Affiliate497-Income/(Loss) Before Income Taxes4,3217.4%(32)-0.1%Provision for Income Taxes1,2271,252Income/(Loss) from Continuing Operations

    $

    3,0945.3%$

    (1,284)-2.6%Loss from Discontinued Operations, Net of Tax(333)(170)Net Income/(Loss)

    $

    2,7614.7%$

    (1,454)-2.9%Basic Earnings/(Loss) per Share of Common Stock:   Income/(Loss) from Continuing Operations$   0.10$ (0.04)   Loss from Discontinued Operations, Net of Tax$ (0.01)$ (0.01)   Net Income/(Loss)$   0.09$ (0.05)Diluted Earnings/(Loss) per Share of Common Stock:   Income/(Loss) from Continuing Operations$   0.10$ (0.04)   Loss from Discontinued Operations, Net of Tax$ (0.01)$ (0.01)   Net Income/(Loss)$   0.09$ (0.05)Weighted Average Shares OutstandingBasic29,48329,373Diluted29,52829,373CAMBREX CORPORATIONStatements of Profit and LossFor the Nine Months Ended September 30, 2011 and 2010(in thousands, except per-share data)20112010% of% ofAmountSalesAmountSalesGross Sales

    $

    187,341$

    162,914Commissions, Allowances and Rebates1,2261,204Net Sales186,115161,710Other2,007374Net Revenues188,122162,084Cost of Goods Sold133,78171.4%115,54870.9%Gross Profit54,34129.0%46,53628.6%Operating ExpensesSelling, General and Administrative Expenses28,09715.0%24,78415.2%Research and Development Expenses8,2474.4%7,9064.9%Restructuring Expenses--1,1870.7%Merger and Acquisition Expenses--7860.5%Total Operating Expenses36,34419.4%34,66321.3%Operating Profit17,9979.6%11,8737.3%Other Expenses/(Income):Interest Expense, net1,7423,602Other (Income)/Expenses, net(271)69Equity in Losses of Partially-Owned Affiliate1,164-Income Before Income Taxes15,3628.2%8,2025.0%Provision for Income Taxes4,6564,137Income from Continuing Operations

    $

    10,7065.7%$

    4,0652.5%(Loss)/Income  from Discontinued Operations, Net of Tax(479)935Net Income

    $

    10,2275.5%$

    5,0003.1%Basic Earnings/(Loss) per Share of Common Stock:   Income from Continuing Operations$
    .36$
    .14   (Loss)/Income from Discontinued Operations, Net of Tax$   (0.01)$
    .03   Net Income$
    .35$
    .17Diluted Earnings/(Loss) per Share of Common Stock:   Income from Continuing Operations$
    .36$
    .14   (Loss)/Income from Discontinued Operations, Net of Tax$   (0.01)$
    .03   Net Income$
    .35$
    .17Weighted Average Shares OutstandingBasic29,45029,341Diluted29,51729,443CAMBREX CORPORATIONConsolidated Balance SheetsAs of September 30, 2011 and December 31, 2010(in thousands)September 30,December 31,Assets20112010Cash and Cash Equivalents

    $

    29,710$

    29,614Trade Receivables, net31,80139,025Inventories, net65,80961,408Prepaid Expenses and Other Current Assets7,0815,082  Total Current Assets134,401135,129Property, Plant and Equipment, net142,446150,483Goodwill38,01537,694Intangible Assets, net4,5114,687Investment in Partially-Owned Affiliate16,81019,709Other Non-Current Assets2,8504,049  Total Assets

    $

    339,033$

    351,751Liabilities and Stockholders' EquityAccounts Payable

    $

    18,372$

    19,480Accrued Expenses and Other Current Liabilities36,50533,503  Total Current Liabilities54,87752,983Long-term Debt99,000115,900Deferred Income Taxes17,19117,893Accrued Pension and Postretirement Benefits38,73943,921Other Non-Current Liabilities11,07713,419  Total Liabilities

    $

    220,884$

    244,116  Stockholders’ Equity

    $

    118,149$

    107,635  Total Liabilities and Stockholders’ Equity

    $

    339,033$

    351,751CAMBREX CORPORATIONReconciliation of GAAP to non-GAAP ResultsFor the Quarters and Nine Months Ended September 30, 2011 and 2010(in thousands)Third Quarter 2011Third Quarter 2010Operating Profit

    $

    5,396$

    1,253Restructuring Expenses-1,187Merger and Acquisition Expenses-711Adjusted Operating Profit5,3963,151Depreciation and Amortization5,7185,388Adjusted EBITDA

    $

    11,114$

    8,539Nine Months 2011Nine Months 2010Operating Profit

    $

    17,997$

    11,873Restructuring Expenses-1,187Merger and Acquisition Expenses-786Adjusted Operating Profit17,99713,846Depreciation and Amortization17,32115,997Adjusted EBITDA

    $

    35,318$

    29,843
    '/>"/>

    SOURCE Cambrex Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Cambrex to Announce Third Quarter 2011 Financial Results on November 3, 2011
    2. Cambrex to Announce Second Quarter 2011 Financial Results on August 2, 2011
    3. Cambrex Reports First Quarter of 2011 Results
    4. Cambrex Reports Fourth Quarter and Full Year 2010 Results
    5. Cambrex to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
    6. Cambrex Zenara Manufacturing Facility Receives European GMP Approval
    7. Shawn P. Cavanagh Appointed Chief Operating Officer of Cambrex
    8. Cambrex Zenara Supplies Product for Launch of Nicorette® in India
    9. Cambrex Acquires Stake in Zenara Pharma
    10. Cambrex to Announce Third Quarter 2010 Financial Results on November 3, 2010
    11. Cambrex Acquires IEP GmbH
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/8/2016)...  The University of Michigan Health System in ... part of the development of four new operating rooms, ... the U.S. to start using new top-of-the-line neurosurgical imaging ... of neurosurgery. --> Karin Muraszko , ... The BrightMatter technology from Synaptive Medical – a highly ...
    (Date:2/8/2016)... 2016  Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) today ... ended December 31, 2015, the Company achieved revenue of $8,195,839, ... same quarter in fiscal 2015. --> ... fiscal year 2016 was $2,068,635, or $.03 per share, up ... share, in the Q2 of fiscal year 2015. Gross margin ...
    (Date:2/8/2016)... , Feb. 8, 2016 ... the addition of the "Label-Free Detection ... Forecasts to 2020" report to their ... announced the addition of the "Label-Free ... Global Forecasts to 2020" report to ...
    Breaking Medicine Technology:
    (Date:2/8/2016)... ... ... Coast Dental has a new way to help parents keep their children's ... Yvonne Dorrian, DMD, is hosting a free seminar on Friday, February 19 from 2 ... 1207 North Peachtree Parkway in Peachtree City. Dr. Dorrian will have healthy snacks, activities, ...
    (Date:2/8/2016)... York, NY (PRWEB) , ... February 08, 2016 , ... ... are too much to handle, you are not alone. According to the Center for ... include heart disease, stroke, type 2 diabetes and certain types of cancer, some of ...
    (Date:2/8/2016)... San Francisco, CA (PRWEB) , ... February 08, 2016 , ... ... helped raise $792,000 to help combat pancreatic cancer. , Gary D. Radine, who recently ... who also was the American Cancer Society’s 2015 CEO of the Year , ...
    (Date:2/8/2016)... ... February 08, 2016 , ... Discover the Rocky Mountain region’s longest ... and 700 companies. Attendees also get to see the most incredible gardens and ... Home Show , at the Colorado Convention Center - 700 14th St. Denver CO, ...
    (Date:2/8/2016)... , ... February 08, 2016 , ... Guruji Mahendra Kumar ... 10th and 11th, 2016 in honor of his birthday on February 10th. During ... Mahendra Trivedi is known by over 250,000 people from over 40 different countries ...
    Breaking Medicine News(10 mins):